Skip to main content

Longeveron stock jumps on Alzheimer’s trial results

Treatment derived from bone marrow shows promise in patients with mild Alzheimer's disease.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.